1 The EIC Accelerator Project

EIC Accelerator Program: Overview

The EIC Accelerator program is a key funding initiative under the European Innovation Council (EIC) aimed at fostering innovation and supporting small and medium-sized enterprises (SMEs) in Europe, particularly those engaged in deep-tech and high-impact projects. It provides financial support through a combination of grants and equity investments to help startups and SMEs develop their groundbreaking ideas into viable products and services.

Funding Structure

The EIC Accelerator offers a dual funding mechanism:

Purpose and Role in the Ecosystem

The EIC Accelerator is designed to bridge the funding gap that many innovative startups face, particularly those in the deep-tech sector that may struggle to attract investment from traditional venture capital sources. By providing both grants and equity, the program not only supports the development of innovative technologies but also enhances the credibility of recipient companies, making them more attractive to private investors. This dual approach helps facilitate further investment, allowing companies to scale effectively.

ALA Diagnostics: Winner of the EIC Accelerator

Company Overview

ALA Diagnostics, S.L., based in Spain, is a pioneering company focused on revolutionizing the diagnosis of multiple sclerosis (MS) through innovative bioinformatics solutions.

Project Overview: ALA DIAGNOSTICS MS KIT

The project, known as ALA DIAGNOSTICS MS KIT, aims to transform the diagnostic process for multiple sclerosis by offering the first bioinformatic diagnostic kit that enables early detection through a simple blood test. This innovation stands to significantly impact the lives of patients by facilitating timely diagnosis and treatment, ultimately improving patient outcomes.

Technology Background

The ALA DIAGNOSTICS MS KIT leverages advanced bioinformatics to analyze biomarkers associated with multiple sclerosis. Traditional methods for diagnosing MS often involve complex procedures, including MRI scans and spinal taps, which can be invasive and time-consuming. The ALA kit simplifies this process by utilizing a blood sample, enabling quicker and less invasive testing.

Key Components of the Technology:

• Bioinformatics Algorithms: The kit employs sophisticated algorithms that analyze specific biomarkers in the blood, which are indicative of MS. These algorithms are trained on extensive datasets, helping to ensure high accuracy in diagnosis.
• Biomarker Identification: Research indicates that certain proteins and molecules in the bloodstream correlate with the presence of MS. The ALA DIAGNOSTICS MS KIT focuses on identifying these biomarkers, allowing for early-stage detection.
• User-Friendly Interface: The kit is designed to be user-friendly, streamlining the testing process for healthcare providers. This accessibility is critical in promoting broader adoption in clinical settings.

Conclusion

The EIC Accelerator program plays a vital role in nurturing innovation within the European startup ecosystem, particularly for deep-tech companies like ALA Diagnostics. By providing substantial financial support through grants and equity, the program enables companies to advance their technologies and bring impactful solutions to market. The ALA DIAGNOSTICS MS KIT exemplifies this mission by offering a groundbreaking approach to diagnosing multiple sclerosis, highlighting the potential of bioinformatics in transforming healthcare.

2 The Funding Rounds

Financing Raised

Since winning the EIC Accelerator in October 2022, ALA Diagnostics, S.L. (Spain) has raised a total of approximately €2.5 million in disclosed funding.

• In October 2022, the company secured €1.4 million from the European Innovation Council through the EIC Accelerator program.
• In June 2023, ALA Diagnostics raised an additional €1.1 million from BeAble Capital.

Funding Rounds: Timing and Amount

Date	Type	Investor/Source	Amount
Oct 2022	Grant (EIC Accelerator)	European Innovation Council (EIC)	€1.4 million
Jun 2023	Venture Round	BeAble Capital	€1.1 million
Total			€2.5 million

These are the principal publicly disclosed funding rounds for ALA Diagnostics since their EIC Accelerator award.

Investor Information

• The main investors since October 2022:
• European Innovation Council (via EIC Accelerator grant).
• BeAble Capital (venture capital; June 2023 round).

There is no public information available about other investors participating in these rounds.

Additional Funding Round Details

ALA Diagnostics was among a select group of deep tech startups to receive blended finance support from the EIC Fund following a highly competitive selection process in which only about 7% of applicants were successful. The blended finance mechanism allows for both grant and equity support up to €17.5 million per company through grants and equity investments by the EIC Fund; however, only part of this—€1.4 million—has been confirmed as received by ALA Diagnostics with further details on any equity component currently undisclosed or pending finalization.

The subsequent funding round led by BeAble Capital added another significant influx of capital (€1.1M), indicating continuing investor confidence but does not specify participation from other co-investors or syndicates.

Company Valuations

No public disclosures regarding pre-money or post-money valuations for any funding rounds involving ALA Diagnostics have been found since their receipt of the EIC Accelerator award.

Exit Events: IPOs, Buyouts, Acquisitions

As of May 2025:

• There have been no reported exit events such as an IPO, acquisition, or buyout involving ALA Diagnostics.
• The company remains privately held and continues to operate independently.

---

Sources

• Dealroom profile – Ala diagnostics
• InnovationMap – Ala diagnostics
• Strata.team – EIC accelerator winners statistics
• European Commission news – New wave deep tech start-ups set to receive accelerator grants and equity

3 The Press Releases

ALA Diagnostics, S.L. from Spain

ALA Diagnostics, S.L., a Spanish company, was a winner of the European Innovation Council (EIC) Accelerator funding program in October 2022. The company's innovative project, the ALA DIAGNOSTICS MS KIT, focuses on revolutionizing the diagnosis of multiple sclerosis with a pioneering bioinformatic diagnostic kit. This kit allows for early detection of multiple sclerosis using a simple blood test, marking a significant advancement in neurological diagnostics.

EIC Accelerator Funding

ALA Diagnostics received funding under the "Grant first" category, which is part of the EIC Accelerator program designed to support small and medium-sized enterprises and startups in developing and commercializing breakthrough technologies. The EIC Accelerator program is highly competitive, with a low success rate, and the funding received by ALA Diagnostics underscores the potential and innovation of their diagnostic kit.

Technology Advancements

The ALA DIAGNOSTICS MS KIT represents a groundbreaking approach to diagnosing multiple sclerosis. By leveraging bioinformatics, the kit enables early detection through a minimally invasive blood test, which can significantly improve patient outcomes by facilitating timely interventions.

Partnerships and Updates

There is no publicly available information on specific partnerships or team updates related to ALA Diagnostics since receiving the EIC Accelerator funding. However, the company's website and social media may provide additional insights into their ongoing projects and collaborations.

Press Releases and Blog Posts

ALA Diagnostics does not appear to have published press releases or blog posts on their website or social media accounts related to the EIC Accelerator funding. However, the company's participation in the EIC program is highlighted in reports discussing the winners of the October 2022 cut-off.

Patents

There is no specific information available regarding patents filed or granted to ALA Diagnostics in relation to their diagnostic kit.

Conclusion

ALA Diagnostics' achievement in securing EIC Accelerator funding highlights the company's innovative potential in the field of multiple sclerosis diagnosis. Their focus on developing a bioinformatic diagnostic kit underscores their commitment to advancing medical diagnostics and improving patient care.

Sources: - EIC Accelerator winners and statistics October 2022

• Aladiagnostics.com
• European Innovation Council

4 The Technology Advancements

ALA Diagnostics, S.L., a Spanish biotech company focused on multiple sclerosis (MS) diagnostics, has not publicly disclosed specific updates regarding EIC Accelerator funding received in October 2022. However, their known advancements prior to and around this period highlight their ongoing efforts to commercialize a novel diagnostic solution.

Current Capabilities
The company is developing a blood-based diagnostic kit designed to detect MS using a patented recombinant protein biomarker and proprietary algorithms. This approach aims to replace invasive cerebrospinal fluid testing with a faster, cheaper alternative suitable for routine clinical use.

Post-2022 Developments
While no explicit post-EIC Accelerator updates are documented in available sources:

• Technology Timeline: As of November 2020, ALA Diagnostics planned market entry within 24 months through the GAEM Foundation’s accelerator program, suggesting initial commercialization efforts were underway circa late 2022/early 2023.
• Clinical Progress: Early results indicated promising accuracy for their EM KIT blood test in identifying MS biomarkers, though recent clinical trial data or peer-reviewed publications remain undisclosed.
• IP Strategy: The company utilizes at least one patented biomarker-protein combination, but no new patents or whitepapers have been reported since the GAEM collaboration announcement.

No verifiable information exists regarding post-October 2022 customer pilots, market demonstrations, or additional funding utilization related to EIC support at the time of writing.

---

Sources

The biotech company ALA Diagnostics joins the GAEM Accelerator

Note: The EIC Accelerator mention in the query lacks corroboration in available sources; all citations reference pre-/around-Funding Period activities.

5 The Partnerships and Customers

ALA Diagnostics, S.L. Overview

ALA Diagnostics, S.L., a Spanish company, was a recipient of the EIC Accelerator funding in October 2022. Unfortunately, specific details about ALA Diagnostics' partnerships, customers, or new relationships formed since receiving the funding are not readily available in the provided search results.

General Information on ALA Diagnostics

As a winner of the EIC Accelerator, ALA Diagnostics, S.L. likely specializes in innovative diagnostic solutions. However, without direct access to their website or specific press releases, it's challenging to outline their current partnerships, customers, or new developments.

Potential Impact of Partnerships and Relationships

In general, partnerships and collaborations in the diagnostics sector can significantly enhance a company's position in the market by:

• Expanding Access to New Technologies: Collaborations often facilitate the adoption of new technologies, which can improve diagnostic capabilities.
• Scaling Operations: Partnerships can provide access to larger markets, resources, and expertise, aiding in scaling up operations.
• Enhancing Market Position: Strong partnerships can bolster a company's reputation and competitiveness in the industry.

Future Prospects

For ALA Diagnostics, S.L., any new partnerships or customer relationships would likely focus on advancing their diagnostic technologies and expanding their reach in the healthcare sector. This could involve collaborations with research institutions, healthcare providers, or other technology firms to further develop and commercialize their diagnostic solutions.

Conclusion

While specific details about ALA Diagnostics' recent partnerships or customers are not available, it's clear that such relationships would be crucial for advancing their diagnostic technologies and market presence.

Sources

• ALA Diagnostics Website
• No additional sources were found that directly relate to ALA Diagnostics, S.L.

6 The Hiring and Company Growth

ALA Diagnostics, S.L. Overview

ALA Diagnostics, S.L., based in Spain, received the EIC Accelerator funding in October 2022. Despite this notable achievement, specific details about the company's current headcount, team size, hiring status, growth rate, and key positions filled recently are not publicly available.

Current Hiring and Team Growth

There is no public information on whether ALA Diagnostics is currently hiring or the extent of their team growth since receiving the EIC funding. Typically, companies in the diagnostics sector might expand their teams to develop new technologies or enhance existing ones.

Current Team Size and Headcount

The current team size and headcount of ALA Diagnostics are not disclosed publicly. This information is often kept private by companies unless they choose to release it through official statements or news releases.

Growth and Funding Impact

The EIC Accelerator funding is designed to support innovative companies in scaling their operations and developing their products. For ALA Diagnostics, this funding likely plays a critical role in accelerating their technological advancements and potentially expanding their team to meet the demands of a growing business.

Key Positions and Future Impact

Without specific details on recently hired key positions, it is difficult to assess their impact on the company's future. However, hiring new team members typically allows companies to enhance their expertise, improve efficiency, and scale their operations more effectively. New hires in critical roles could help ALA Diagnostics develop more innovative diagnostic solutions and expand its market presence.

Management Changes

There is no publicly available information regarding major changes in ALA Diagnostics' management or founding team since they received the EIC Accelerator funding.

Conclusion

While specific details about ALA Diagnostics' hiring, team size, and management changes are not available, the EIC Accelerator funding suggests that the company is poised for growth and technological advancement. Further announcements or releases from the company would provide more insight into these aspects.

---

Sources: - Spain 5-ALA Industry Research Report 2025

• In Vitro Diagnostics - Spain
• Challenges in resource allocation of diagnostic tests in Spain
• Board - MedTech Europe
• Erytra Eflexis
• Beckman Coulter Diagnostics
• How Many Employees Do You Really Need?
• 10 Employee Engagement Statistics You Need to Know in 2024
• Common Positions in a Company

7 The Media Features and Publications

Overview of ALA Diagnostics, S.L.

ALA Diagnostics, S.L. is a Spanish company that has gained recognition for its innovative diagnostic solutions. It received the EIC Accelerator funding in October 2022, marking a significant milestone in its development.

Media Features

Currently, there is limited publicly available information on specific media features or publications that have named ALA Diagnostics, S.L. The company's involvement in media coverage or publications is not widely documented in the available search results.

Publications and Content

There are no specific publications or content pieces directly referencing ALA Diagnostics, S.L. in the available search results.

Podcasts and Interviews

No information is available on podcasts or interviews featuring the team of ALA Diagnostics, S.L.

Conference and Fair Visits

While there is no specific information on ALA Diagnostics, S.L.'s participation in conferences or fairs, such events are crucial for companies in the diagnostic sector to showcase their products and network with industry professionals.

Involvement in Events

Details about ALA Diagnostics, S.L.'s involvement in events, such as conferences or workshops, are not readily available in the current search results.

Conclusion

ALA Diagnostics, S.L. is a Spanish company focused on diagnostics, having secured EIC Accelerator funding in October 2022. However, detailed information about its media presence, publications, or event participation is limited based on the current search results.

Sources:

• Development Aid
• Dun & Bradstreet